Analytical Data
-
Gene name
EGFL7
- Application
-
Alternative Names
EGFL7；MEGF7；Epidermal growth factor-like Protein 7
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UHF1
-
Expression Region
24-273aa
-
AA Sequence
YRPGRRV CAVRAHGDPV SESFVQRVYQ PFLTTCDGHR ACSTYRTIYR TAYRRSPGLA PARPRYACCP GWKRTSGLPG ACGAAICQPP CRNGGSCVQP GRCRCPAGWR GDTCQSDVDE CSARRGGCPQ RCVNTAGSYW CQCWEGHSLS ADGTLCVPKG GPPRVAPNPT GVDSAMKEEV QRLQSRVDLL EEKLQLVLAP LHSLASQALE HGLPDPGSLL VHSFQQLGRI DSLSEQISFL EEQLGSCSCK KDS
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EGFL7 (EPIDERMAL GROWTH FACTOR-LIKE 7) is a member of the epidermal growth factor (EGF) family and plays a critical role in various biological processes, including angiogenesis, cell migration, and tissue repair. Its expression has been notably observed in endothelial cells and during embryonic development, suggesting its involvement in vascular formation and homeostasis. The increasing interest in EGFL7 is driven by its potential as a therapeutic target in diseases characterized by abnormal angiogenesis, such as cancer and ischemic disorders. Furthermore, research has shown that EGFL7 can modulate the activity of vascular endothelial growth factor (VEGF), enhancing the understanding of its role in hypoxic conditions. Recombinant EGFL7 proteins are being studied for their ability to promote endothelial cell proliferation and enhance angiogenic responses in vitro and in vivo. These investigations aim to elucidate the mechanisms through which EGFL7 contributes to endothelial biology and to explore its application in regenerative medicine and cancer therapy. Additionally, the production of recombinant EGFL7 facilitates the assessment of its structural and functional properties, paving the way for potential applications in therapeutic interventions targeting angiogenic pathways. Overall, the study of EGFL7 as a recombinant protein holds promise for advancing our knowledge of vascular biology and developing novel strategies for managing diseases associated with abnormal blood vessel formation.
